IL-6 Receptor Blockers: Mechanism & Uses
IL-6 receptor blockers are medications that inhibit the signaling molecule interleukin-6, thereby reducing excessive inflammation. They are used to treat autoimmune diseases and severe inflammatory conditions.
Things worth knowing about "IL-6 receptor blocker"
IL-6 receptor blockers are medications that inhibit the signaling molecule interleukin-6, thereby reducing excessive inflammation. They are used to treat autoimmune diseases and severe inflammatory conditions.
What Are IL-6 Receptor Blockers?
IL-6 receptor blockers (also called interleukin-6 receptor antagonists) are a class of medications that specifically target the receptor for the body's own signaling molecule interleukin-6 (IL-6). IL-6 is a cytokine – a signaling protein of the immune system that initiates and coordinates inflammatory responses. In certain diseases, IL-6 is produced in excess, leading to chronic or life-threatening inflammation. IL-6 receptor blockers prevent IL-6 from binding to its target cells, thereby interrupting the inflammatory cascade.
Mechanism of Action
Interleukin-6 normally binds to specific receptors on the surface of immune cells and other body cells to activate inflammatory processes. IL-6 receptor blockers are monoclonal antibodies that selectively bind to this receptor – either the membrane-bound (cell-attached) or the soluble form. This prevents IL-6 from exerting its effects, and the downstream inflammatory signals are suppressed. As a result, inflammatory markers such as C-reactive protein (CRP) in the blood are significantly reduced.
Approved Active Substances
- Tocilizumab (e.g., Actemra): The most widely used IL-6 receptor blocker, approved for multiple indications.
- Sarilumab (e.g., Kevzara): Also a monoclonal antibody against the IL-6 receptor, primarily used in rheumatoid arthritis.
- Siltuximab (e.g., Sylvant): Binds directly to IL-6 itself (not strictly a receptor blocker), used in Castleman disease.
Indications
IL-6 receptor blockers are used in various diseases in which excessive IL-6-mediated inflammation plays a central role:
- Rheumatoid arthritis: Chronic joint inflammation, where IL-6 receptor blockers are used as second- or third-line therapy.
- Juvenile idiopathic arthritis: Inflammatory joint disease in children and adolescents.
- Adult-onset Still's disease: A rare systemic inflammatory disorder in adults.
- Giant cell arteritis: Inflammation of large blood vessels, predominantly in older adults.
- Cytokine release syndrome (CRS): A potentially life-threatening excessive immune reaction, for example after CAR-T cell therapy.
- COVID-19: In severe cases involving a cytokine storm, IL-6 receptor blockers (especially tocilizumab) have been used successfully.
- Neuromyelitis optica spectrum disorder (NMOSD): A rare autoimmune disease of the nervous system.
Dosage and Administration
Depending on the specific drug and indication, IL-6 receptor blockers are administered either as an intravenous infusion in a clinical setting or as a subcutaneous injection (under the skin). Dosing intervals range from weekly to monthly administration. The exact dosage is determined individually by the treating physician.
Side Effects
Since IL-6 receptor blockers suppress immune activity, they can increase susceptibility to infections. Common and important side effects include:
- Increased risk of infection: Particularly respiratory and urinary tract infections, but also serious infections such as tuberculosis.
- Changes in blood lipid levels: Increases in cholesterol and triglycerides.
- Neutropenia: A reduction in certain white blood cells (neutrophilic granulocytes).
- Elevated liver enzymes: Transient increases in liver enzyme levels.
- Injection site reactions: When administered subcutaneously.
- Gastrointestinal complaints: Nausea, abdominal pain, or diarrhea.
Contraindications and Precautions
Before starting therapy with IL-6 receptor blockers, patients should be screened for active infections, especially tuberculosis. Use is contraindicated in the presence of active severe infections. Live vaccines should be avoided during treatment. Regular blood count monitoring is required throughout the course of therapy.
References
- European Medicines Agency (EMA): Product information for tocilizumab (RoActemra/Actemra) and sarilumab (Kevzara). www.ema.europa.eu (accessed 2024).
- Smolen JS et al. – Rheumatoid arthritis. Nature Reviews Disease Primers, 2018; 4: 18001. doi:10.1038/nrdp.2018.1
- Tanaka T, Narazaki M, Kishimoto T – IL-6 in inflammation, immunity, and disease. Cold Spring Harbor Perspectives in Biology, 2014; 6(10): a016295.
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: IL-6 receptor blocker